YUKI GOSEI KOGYO CO.,LTD. Logo

YUKI GOSEI KOGYO CO.,LTD.

Manufacturer of fine chemicals via organic synthesis for pharma and industrial sectors.

4531 | T

Overview

Corporate Details

ISIN(s):
JP3946400003
LEI:
Country:
Japan
Address:
中央区日本橋人形町三丁目10番4号

Description

YUKI GOSEI KOGYO CO.,LTD. is a manufacturer specializing in the research, development, and production of fine chemical products through organic synthesis. Leveraging its proprietary technologies developed since its foundation in 1947, the company produces a diverse portfolio that includes amino acids, food additives, and materials for the pharmaceutical sector, supporting drug discovery and generic drug development. The company also manufactures industrial functional materials, including ingredients for semiconductors and silicon wafers. In addition to its product lines, YUKI GOSEI KOGYO offers contract manufacturing services for both medical and chemical applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-06-24 03:44
内部統制報告書-第104期(2023/04/01-2024/03/31)
Japanese ZIP 22.7 KB
2024-06-24 03:41
確認書
Japanese ZIP 8.8 KB
2024-06-24 03:38
有価証券報告書-第104期(2023/04/01-2024/03/31)
Japanese ZIP 701.5 KB
2024-02-13 02:39
確認書
Japanese ZIP 8.8 KB
2024-02-13 02:37
四半期報告書-第104期第3四半期(2023/10/01-2023/12/31)
Japanese ZIP 158.7 KB
2023-11-13 02:29
確認書
Japanese ZIP 8.8 KB
2023-11-13 02:27
四半期報告書-第104期第2四半期(2023/07/01-2023/09/30)
Japanese ZIP 187.1 KB
2023-08-10 03:23
確認書
Japanese ZIP 8.8 KB
2023-08-10 03:18
四半期報告書-第104期第1四半期(2023/04/01-2023/06/30)
Japanese ZIP 152.8 KB
2023-06-26 06:42
内部統制報告書-第103期(2022/04/01-2023/03/31)
Japanese ZIP 22.7 KB
2023-06-26 06:40
確認書
Japanese ZIP 8.8 KB
2023-06-26 06:36
有価証券報告書-第103期(2022/04/01-2023/03/31)
Japanese ZIP 695.4 KB
2023-02-13 02:50
確認書
Japanese ZIP 8.8 KB
2023-02-13 02:48
四半期報告書-第103期第3四半期(2022/10/01-2022/12/31)
Japanese ZIP 161.8 KB
2022-11-11 02:49
確認書
Japanese ZIP 8.9 KB

Automate Your Workflow. Get a real-time feed of all YUKI GOSEI KOGYO CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for YUKI GOSEI KOGYO CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for YUKI GOSEI KOGYO CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.